Your browser doesn't support javascript.
loading
The Application of Static Magnetic Stimulation Reduces Survival of SH-SY5Y Neuroblastoma Cells.
Medeiros, Helouise Richardt; Fagundes Assumpção, José Antônio; Stein, Dirson João; Filippi-Chiela, Eduardo Cremonese; Fregni, Felipe; Caumo, Wolnei; Stefani Sanches, Paulo Roberto; Torres, Iraci L S.
Afiliação
  • Medeiros HR; Laboratory of Pain Pharmacology and Neuromodulation, Preclinical Studies-Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • Fagundes Assumpção JA; Post-Graduate Program in Medicine, Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Stein DJ; Translational Nucleus, Pain Pharmacology and Neuromodulation, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • Filippi-Chiela EC; Department of Pharmacology and Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA, U.S.A.
  • Fregni F; Laboratory of Pain Pharmacology and Neuromodulation, Preclinical Studies-Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • Caumo W; Post-Graduate Program in Medicine, Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Stefani Sanches PR; Translational Nucleus, Pain Pharmacology and Neuromodulation, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • Torres ILS; Department of Morphological Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Anticancer Res ; 43(4): 1427-1436, 2023 Apr.
Article em En | MEDLINE | ID: mdl-36974821
ABSTRACT
BACKGROUND/

AIM:

Central nervous system cancer is still a major public health issue. The effectiveness of treatments is limited and varies depending on the severity of disease. Therefore, there is a demand for the development of novel therapies. Static magnetic stimulation (SMS) emerges as a new therapeutic option. The aim of this study was to evaluate the SMS effects on neuroblastoma cells in culture. MATERIALS AND

METHODS:

SH-SY5Y neuroblastoma cells were exposed to 0.3T SMS for 6, 12, 24, 36, 72 h, and 6 days. Cell viability (MTT), cell death (annexin-V/PI staining) and cell cycle (DNA content), cell proliferation (CFSE), autophagy (acridine orange), and total mitochondrial mass (MitoTracker™ Red) were analyzed to establish the cellular response to SMS.

RESULTS:

The viability of SH-SY5Y cells was reduced after exposure to SMS for 24 h and 6 days (p<0.05), without differences for the other times (p>0.05); however, this effect was not related to cell death or cell cycle arrest (p>0.05). In contrast, the viability of human malignant melanoma (HMV-II) cells, used as a tumoral control, was not affected. In addition, stimulated SH-SY5Y cells presented a decrease in mitochondrial mass at both exposure times and a reduction in autophagy and cell proliferation after 6 days (p<0.05).

CONCLUSION:

SMS application appears to be a promising adjuvant therapy for the treatment of neuroblastoma since it decreases the survival of SH-SY5Y neuroblastoma cells.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuroblastoma Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuroblastoma Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article